John J Treanor MD

Infectious Disease•Rochester, NY

Chief of the Infectious Diseases Division of the Department of Medicine at the University of Rochester Medical Center

Join to View Full Profile

601 Elmwood AveBox MedRochester, NY 14642
Phone+1 585-275-5871
Fax+1 585-273-1055

Education & Training

University of Rochester Medical CenterFellowship, Infectious Disease, 1982 - 1985
University of Vermont Medical CenterResidency, Internal Medicine, 1979 - 1981
University of Rochester School of Medicine and DentistryClass of 1979

Certifications & Licensure

NY State Medical License 1982 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults Start of enrollment: 2004 Nov 01
Completed
Phase 2, Phase 3
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Start of enrollment: 2007 Sep 15
Completed
Phase 3
Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine Start of enrollment: 2008 Jul 01
Completed
Phase 1
Phase 1 Norwalk Vaccine Study Start of enrollment: 2008 Nov 01
Completed
Phase 1
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7 Start of enrollment: 2010 Jul 01
Completed
Phase 1
Effects of Age on Response to the 2009 H1N1 Virus Vaccine Start of enrollment: 2010 Mar 01
Completed
Phase 1, Phase 2
Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children Start of enrollment: 2010 Mar 01
Withdrawn
Phase 4
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza Start of enrollment: 2010 Sep 01
Completed
Phase 1
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications Start of enrollment: 2010 Sep 01
Completed
Phase 2
Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults Start of enrollment: 2012 Mar 01
Completed
Phase 1
Norovirus Bivalent-Vaccine Efficacy Study Start of enrollment: 2012 Jul 16
Completed
Phase 1, Phase 2
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults Start of enrollment: 2012 May 01
Completed
Phase 1, Phase 2
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines Start of enrollment: 2012 Sep 01
Completed
Phase 1
Age and Response to Flu Vaccines Start of enrollment: 2017 Dec 14
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

3 citations
Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Jiong Wang, Dongmei Li, Sheldon Perry, Shannon P. Hilchey, Alexander Wiltse
Mbio. 2021-07-06
12 citations
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers
Myron M. Levine, Salim Abdullah, Yaseen M. Arabi, Delese Mimi Darko, Anna P. Durbin
Clinical Infectious Diseases. 2021-06-01
4 citations
Gaps in Serologic Immunity against Contemporary Swine-Origin Influenza A Viruses among Healthy Individuals in the United States.
Joshua N. Lorbach, Theresa Fitzgerald, Carolyn Nolan, Jacqueline M. Nolting, John J. Treanor
Viruses. 2021-01-18

Press Mentions

It's Time for Your 2019 Flu Shot: Why October Is the Best MonthAugust 26th, 2019
Can You Get the Flu Shot Too Early?September 12th, 2018
Family Flu Alert: Nasal Spray No Longer an Option for KidsOctober 27th, 2017
Join now to see all

John J Treanor MD

Dr. Treanor is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.